Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Sponsors Face Tight Controls On Meetings With US FDA After CR Letters

Executive Summary

Meetings are intended to help generic sponsors understand deficiencies, but agency won't let them run past 30 minutes.
Advertisement

Related Content

US FDA Appears To Have Avoided Shutdown-Related ANDA Bolus
ANDA Sponsors Need To 'Slow Down' And Focus On Quality, US FDA Generics Director Says
US FDA's Generics Program Reaches 'Steady State' Milestone
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
US FDA Commits To Meeting With Complex ANDA Sponsors, Works Hard To Avoid It

Topics

Advertisement
UsernamePublicRestriction

Register

PS124387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel